Fosrenol data show evidence of trends towards improved bone formation in CKD stage 5 patients
Treatment with the phosphate binder FOSRENOL(R) (lanthanum carbonate) was associated with slight improvements in bone formation in chronic kidney disease (CKD) Stage 5 patients with hyperphosphatemia (high phosphorus levels in the blood), according to long-term (two-year) data presented at the American Society of Nephrology (ASN) meeting. Additional studies presented at ASN document the efficacy and safety of the reformulated and higher-dose FOSRENOL tablets.